Symbols / THMO
THMO Chart
About
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 1.58K |
| Enterprise Value | 4.33M | Income | -14.74M | Sales | 9.61M |
| Book/sh | 0.12 | Cash/sh | 0.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 25 | IPO | — |
| P/E | — | Forward P/E | 0.00 | PEG | — |
| P/S | 0.00 | P/B | 0.00 | P/C | — |
| EV/EBITDA | -0.89 | EV/Sales | 0.45 | Quick Ratio | 0.28 |
| Current Ratio | 0.52 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.98 | EPS next Y | 0.20 | EPS Growth | — |
| Revenue Growth | 6.40% | Earnings | 2024-05-17 17:00 | ROA | -25.50% |
| ROE | -8.02% | ROIC | — | Gross Margin | 21.10% |
| Oper. Margin | -20.35% | Profit Margin | -153.43% | Shs Outstand | 15.85M |
| Shs Float | 1.76M | Short Float | 0.30% | Short Ratio | 1.44 |
| Short Interest | — | 52W High | 0.00 | 52W Low | 0.00 |
| Beta | 14.61 | Avg Volume | 394.00 | Volume | 100.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-04-03 | reit | HC Wainwright & Co. | — → Buy | $5 |
- ThermoGenesis Holdings: Micro?Cap Volatility Meets Quiet Newsflow As Traders Scan The Horizon - AD HOC NEWS Wed, 11 Feb 2026 08
- Why Is ThermoGenesis (THMO) Stock Down 37% Today? - InvestorPlace Wed, 12 Jun 2024 07
- Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Yahoo Finance ue, 24 Jun 2025 07
- ThermoGenesis Holdings (THMO): Micro?cap volatility, quiet newsflow, and an unforgiving year for spe - AD HOC NEWS hu, 01 Jan 2026 08
- THMO Stock Alert: Why ThermoGenesis Is Up 95% Today - InvestorPlace Wed, 15 Mar 2023 07
- ThermoGenesis Holdings, Inc. Receives A Notice of Default from Boyalife Group, Inc - marketscreener.com hu, 07 Nov 2024 08
- 10 Best Immunotherapy Stocks To Buy Now - Yahoo Finance ue, 11 Oct 2022 07
- ThermoGenesis Holdings: Micro?Cap Volatility, Shrinking Float and a Market Still Waiting for a Story - AD HOC NEWS Fri, 13 Feb 2026 04
- Why Is ThermoGenesis (THMO) Stock Up 54% Today? - InvestorPlace hu, 16 Mar 2023 07
- Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today? - InvestorPlace Wed, 12 Jun 2024 07
- Why Is CXApp (CXAI) Stock Up 15% Today? - InvestorPlace hu, 16 Mar 2023 07
- FedEx Layoffs 2024: What to Know About the Latest FDX Job Cuts - InvestorPlace Wed, 12 Jun 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 7894737 | 3000000 | — | Conversion of Exercise of derivative security at price 0.38 per share. | XU XIAOCHUN | Chief Executive Officer | — | 2024-06-28 00:00:00 | I |
| 1 | 4113158 | 1563000 | — | Conversion of Exercise of derivative security at price 0.38 per share. | XU XIAOCHUN | Chief Executive Officer | — | 2024-03-15 00:00:00 | I |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.38M | -5.27M | -5.80M |
| TotalUnusualItems | -2.36M | 0.00 | 652.00K |
| TotalUnusualItemsExcludingGoodwill | -2.36M | 0.00 | 652.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.98M | -11.27M | -11.38M |
| ReconciledDepreciation | 1.15M | 926.00K | 633.00K |
| ReconciledCostOfRevenue | 7.51M | 7.77M | 5.80M |
| EBITDA | -7.74M | -5.27M | -5.14M |
| EBIT | -8.89M | -6.20M | -5.78M |
| NetInterestIncome | -10.03M | -5.62M | -6.10M |
| InterestExpense | 10.03M | 5.62M | 6.10M |
| NormalizedIncome | -15.61M | -11.27M | -12.03M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.98M | -11.27M | -11.38M |
| TotalExpenses | 16.02M | 16.68M | 16.52M |
| TotalOperatingIncomeAsReported | -8.61M | -6.19M | -7.23M |
| DilutedAverageShares | 2.37M | 1.04M | 262.13K |
| BasicAverageShares | 2.37M | 1.04M | 262.13K |
| DilutedEPS | -7.59 | -10.87 | -43.41 |
| BasicEPS | -7.59 | -10.87 | -43.41 |
| DilutedNIAvailtoComStockholders | -17.98M | -11.27M | -11.38M |
| NetIncomeCommonStockholders | -17.98M | -11.27M | -11.38M |
| NetIncome | -17.98M | -11.27M | -11.38M |
| MinorityInterests | 944.00K | 542.00K | 501.00K |
| NetIncomeIncludingNoncontrollingInterests | -18.92M | -11.81M | -11.88M |
| NetIncomeContinuousOperations | -18.92M | -11.81M | -11.88M |
| PretaxIncome | -18.92M | -11.81M | -11.88M |
| OtherIncomeExpense | -2.31M | -3.00K | 1.45M |
| OtherNonOperatingIncomeExpenses | 49.00K | -3.00K | 802.00K |
| SpecialIncomeCharges | -2.36M | 0.00 | 652.00K |
| OtherSpecialCharges | 326.00K | -652.00K | |
| WriteOff | 2.04M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | -10.03M | -5.62M | -6.10M |
| InterestExpenseNonOperating | 10.03M | 5.62M | 6.10M |
| OperatingIncome | -6.57M | -6.19M | -7.23M |
| OperatingExpense | 8.51M | 8.90M | 10.72M |
| ResearchAndDevelopment | 1.28M | 1.66M | 2.21M |
| SellingGeneralAndAdministration | 7.22M | 7.24M | 8.52M |
| GrossProfit | 1.93M | 2.71M | 3.49M |
| CostOfRevenue | 7.51M | 7.77M | 5.80M |
| TotalRevenue | 9.45M | 10.48M | 9.29M |
| OperatingRevenue | 9.45M | 10.48M | 9.29M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 3.62M | 1.04M | 264.71K |
| ShareIssued | 3.62M | 1.04M | 264.71K |
| NetDebt | 5.66M | 2.56M | 2.78M |
| TotalDebt | 10.56M | 10.37M | 10.46M |
| TangibleBookValue | -1.67M | 2.23M | 1.73M |
| InvestedCapital | 5.99M | 11.04M | 13.89M |
| WorkingCapital | -6.58M | -625.00K | 8.62M |
| NetTangibleAssets | -1.67M | 2.23M | 1.73M |
| CapitalLeaseObligations | 2.90M | 3.63M | 398.00K |
| CommonStockEquity | -1.67M | 4.30M | 3.83M |
| TotalCapitalization | -1.67M | 4.30M | 13.07M |
| TotalEquityGrossMinorityInterest | -3.58M | 3.32M | 3.40M |
| MinorityInterest | -1.92M | -973.00K | -431.00K |
| StockholdersEquity | -1.67M | 4.30M | 3.83M |
| GainsLossesNotAffectingRetainedEarnings | 114.00K | 111.00K | 31.00K |
| OtherEquityAdjustments | 114.00K | 111.00K | 31.00K |
| RetainedEarnings | -284.17M | -266.19M | -264.66M |
| AdditionalPaidInCapital | 282.38M | 270.38M | 268.46M |
| CapitalStock | 4.00K | 1.00K | 0.00 |
| CommonStock | 4.00K | 1.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 14.82M | 16.06M | 17.25M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.05M | 4.55M | 10.91M |
| OtherNonCurrentLiabilities | 27.00K | 17.00K | 20.00K |
| NonCurrentDeferredLiabilities | 127.00K | 911.00K | 1.24M |
| NonCurrentDeferredRevenue | 127.00K | 911.00K | 1.24M |
| LongTermDebtAndCapitalLeaseObligation | 2.90M | 3.63M | 9.64M |
| LongTermCapitalLeaseObligation | 2.90M | 3.63M | 398.00K |
| LongTermDebt | 9.24M | ||
| CurrentLiabilities | 11.76M | 11.51M | 6.35M |
| OtherCurrentLiabilities | 1.48M | 1.28M | 957.00K |
| CurrentDeferredLiabilities | 670.00K | 782.00K | 719.00K |
| CurrentDeferredRevenue | 670.00K | 782.00K | 719.00K |
| CurrentDebtAndCapitalLeaseObligation | 7.66M | 6.74M | 813.00K |
| CurrentDebt | 7.66M | 6.74M | 813.00K |
| OtherCurrentBorrowings | 7.66M | 6.74M | 813.00K |
| PayablesAndAccruedExpenses | 1.96M | 2.71M | 3.86M |
| CurrentAccruedExpenses | 1.01M | 1.89M | 2.58M |
| InterestPayable | 634.00K | 1.49M | 2.23M |
| Payables | 948.00K | 820.00K | 1.28M |
| AccountsPayable | 948.00K | 820.00K | 1.28M |
| TotalAssets | 11.23M | 19.39M | 20.65M |
| TotalNonCurrentAssets | 6.05M | 8.50M | 5.69M |
| OtherNonCurrentAssets | 256.00K | 1.26M | 1.76M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 2.07M | 2.10M |
| OtherIntangibleAssets | 1.29M | 1.32M | |
| Goodwill | 0.00 | 781.00K | 781.00K |
| NetPPE | 5.80M | 5.18M | 1.83M |
| AccumulatedDepreciation | -7.58M | -7.17M | -6.83M |
| GrossPPE | 13.37M | 12.35M | 8.66M |
| Leases | 1.55M | 932.00K | 932.00K |
| OtherProperties | 3.21M | 3.92M | 571.00K |
| MachineryFurnitureEquipment | 8.61M | 7.50M | 7.16M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.18M | 10.88M | 14.96M |
| OtherCurrentAssets | 825.00K | 1.51M | 1.58M |
| PrepaidAssets | 1.58M | ||
| Inventory | 1.41M | 3.33M | 5.37M |
| Receivables | 949.00K | 1.86M | 733.00K |
| AccountsReceivable | 949.00K | 1.86M | 733.00K |
| AllowanceForDoubtfulAccountsReceivable | -4.00K | -149.00K | -156.00K |
| GrossAccountsReceivable | 953.00K | 2.01M | 889.00K |
| CashCashEquivalentsAndShortTermInvestments | 2.00M | 4.18M | 7.28M |
| CashAndCashEquivalents | 2.00M | 4.18M | 7.28M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -5.45M | -7.68M | -6.71M |
| IssuanceOfCapitalStock | 2.86M | 4.58M | 6.83M |
| CapitalExpenditure | -1.73M | -400.00K | -93.00K |
| InterestPaidSupplementalData | 1.63M | 2.81M | 2.38M |
| EndCashPosition | 2.00M | 4.18M | 7.28M |
| BeginningCashPosition | 4.18M | 7.28M | 7.16M |
| EffectOfExchangeRateChanges | -1.00K | -6.00K | 0.00 |
| ChangesInCash | -2.18M | -3.10M | 119.00K |
| FinancingCashFlow | 3.28M | 4.59M | 6.83M |
| CashFlowFromContinuingFinancingActivities | 3.28M | 4.59M | 6.83M |
| ProceedsFromStockOptionExercised | 421.00K | 3.00K | 0.00 |
| NetCommonStockIssuance | 2.86M | 4.58M | 6.83M |
| CommonStockIssuance | 2.86M | 4.58M | 6.83M |
| InvestingCashFlow | -1.73M | -400.00K | -93.00K |
| CashFlowFromContinuingInvestingActivities | -1.73M | -400.00K | -93.00K |
| CapitalExpenditureReported | -1.73M | -400.00K | -93.00K |
| OperatingCashFlow | -3.72M | -7.28M | -6.62M |
| CashFlowFromContinuingOperatingActivities | -3.72M | -7.28M | -6.62M |
| ChangeInWorkingCapital | 1.99M | -831.00K | -1.72M |
| ChangeInOtherWorkingCapital | -1.59M | -888.00K | -443.00K |
| ChangeInOtherCurrentLiabilities | 181.00K | 330.00K | -323.00K |
| ChangeInPayablesAndAccruedExpense | 227.00K | -1.07M | 74.00K |
| ChangeInAccruedExpense | 97.00K | -687.00K | 148.00K |
| ChangeInInterestPayable | 120.00K | -738.00K | 149.00K |
| ChangeInPayable | 130.00K | -386.00K | -74.00K |
| ChangeInAccountPayable | 130.00K | -386.00K | -74.00K |
| ChangeInPrepaidAssets | 682.00K | -139.00K | -700.00K |
| ChangeInInventory | 1.57M | 2.07M | -1.03M |
| ChangeInReceivables | 915.00K | -1.13M | 703.00K |
| ChangesInAccountReceivables | 915.00K | -1.13M | 703.00K |
| OtherNonCashItems | 8.30M | 3.49M | 3.63M |
| StockBasedCompensation | 39.00K | 267.00K | 2.56M |
| ProvisionandWriteOffofAssets | 1.36M | 667.00K | 864.00K |
| AssetImpairmentCharge | 2.04M | 2.00K | -56.00K |
| DepreciationAmortizationDepletion | 1.15M | 926.00K | 633.00K |
| DepreciationAndAmortization | 1.15M | 926.00K | 633.00K |
| OperatingGainsLosses | 326.00K | 11.00K | -652.00K |
| GainLossOnSaleOfPPE | 0.00 | 11.00K | 0.00 |
| NetIncomeFromContinuingOperations | -18.92M | -11.81M | -11.88M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for THMO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|